Each weekend must end creating the new week ahead of us. We had plenty of time to read Barron's and the IBD and watch Friday's Mad Money. We know what the 14 key economic data points are next week. We know the 26 or so relevant earnings calls coming out next week. We know all of that, but we don't have a solid feel for the direction of the market this coming week. Usually, with some degree of accuracy we go out on a limb and say a point up or two points down.
Let work through each day one at a time.
Monday
Cramer wants to get the earnings call from CLNE to get a read on the nat gas market. So? We also get to see how badly overdrawn we are in the checkbook. Not my check book. We haven't bounced a check in years. Ok that is not exactly true, we did bounce a check a couple of weeks ago, but it was a whopper. When we bounce a check, we don't muck around. The treasury budget report comes out and we get to see how big the deficit grew. Not really a market mover but worth keeping an eye out for. Look for PNY Piedmont Nat Gas to miss tomorrow as all the nat gas fold had a very mild winter and the lack of cold caused a lack of profit.
Tuesday
Chevron has an analyst meeting and it should be interesting as to the feel for the energy sector. We also have some retail reports that are looking for some nice numbers. We are thinking that once you back out the autos, the number will make Mr. Market unhappy. MED Medifast reports earnings and a lot of folk are expecting them to make up for last quarters lousy report. Stocktwits, Motely Fool, and the Journal are all saying beat. WE DO NOT OWN MED, but when that many people like a stock, we see disappointment. Look for a meet or miss.
Wednesday
FSS Federal Signal reports earnings (or lack there of on Wednesday). They customize fire trucks and ambulances and other municipal type vehicles. (Does that sound like a fun market to be in for the last three years. Not one of their customers have a dime.) They have debt up the siren and things do not look good. I am watching it to see if municipalities are starting to spend money. (Keep in mind PADI has a division that sells high school books.) Mortgage Purchase applications get reported along with the oil inventory report and import export prices. We can't get a volatile read on any of those. Look for a flat day, barring any Eurodrama.
Thursday
We have initial jobless claims and they should continue to fall. We have the Philadelphia Fed report. The smart folk are thinking it will continue to climb and we think it will take a breather this month and disappoint a lot of folk. Look for a down day.
Friday
We have consumer price index which should go up a bit even after backing out food and fuel. Industrial production is guessed to be down, which flys in contrast to the Philly Fed and Empire State expectations. (That is a real mixed message)
So our guess is a down week, say 1.5%. Again we do not have a lot of confidence in that guess, but that is how I am reading the tea leaves.
Take A Generic and Call Me In the Morning
As promised we spent some time reading the last two 10Qs for ACET. Here are the SEC links to those reports if you want to play along.
Dec (Year End) 2011 Earnings
Sep 2011 Earnings
We found no real surprises there good or bad. We did see (and having been seeing this a lot in recent filings) a cloud of accounting regulation changes that might make historical comparatives tricky at best. The most common citings are Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs, Presentation of Comprehensive Income, Presentation of Comprehensive Income, and Balance Sheet (Topic 210), Disclosures about Offsetting Assets and Liabilities. Now each SEC filing for every publically held company MUST explain how the new rules and regs will impact them. We as share holders have the burden of trying to figure out we might compare Q1 2012 to Q1 2011.
We will not pretend to know how to do that, but since we are only dealing with a handful of core accounts, I am comfortable knowing there are those who do an adequate job of that kind of forensic review. After reviewing the two quarters as I say, we still like the stock. The only negative things we could see were forward looking comments such as, " . . global spending for medicines will reach nearly $1.1 trillion by 2015, reflecting a slowing compound annual rate of growth of 3 - 6 percent over the next five years. This compares with 6.2 percent annual growth over the past five years."
Similar cautionary statements could be implied in the other two key segments of the company, specialty chemicals and agricultural protection. We will be adding to this position this week after seeing what this 4% pop on Friday does to the volume and direction of the stock.
Keep an eye on your stops and let's have a great week.
Salve Lucrum